Médicos abogan por nuevos esfuerzos para combatir al Chagas, un asesino silencioso
By Paula Andalo
La enfermedad de Chagas, causada por un parásito, afecta principalmente a personas en las zonas rurales de Latinoamérica. Pero se estima que 300,000 personas en Estados Unidos viven con la enfermedad, que puede causar problemas cardíacos graves. Defensores de pacientes piden esfuerzos mucho más agresivos para combatirla.
Doctors Advocate Fresh Efforts to Combat Chagas Disease, a Silent Killer
By Paula Andalo
Chagas disease, caused by a parasite, affects people primarily in rural Latin America. But an estimated 300,000 residents of the U.S. have the disease, which can cause serious heart problems. Patient advocates call for much more aggressive efforts to fight it.
The CDC Works to Overhaul Lab Operations After Covid Test Flop
By Sam Whitehead
In early 2020, U.S. public health labs received covid-19 tests from the Centers for Disease Control and Prevention that were flawed, as a result of poor design and contamination. Now the CDC is overhauling its lab operations, but efforts to be better prepared for future threats won’t be easy, observers say.
Tribal Health Workers Aren’t Paid Like Their Peers. See Why Nevada Changed That.
By Jazmin Orozco Rodriguez
Community health workers, who often help patients get to their appointments and pick up prescriptions for them, have increasingly been recognized as an integral part of treating chronic illnesses. But state-run Medicaid programs don’t always reimburse them equally, usually excluding those who work on tribal lands.
Daily Edition for Friday, August 18, 2023
Blue Shield Says It Will Broaden Prescription Vendors, Rely Less On CVS: Oakland-based Blue Shield of California, one of the largest health insurance companies in the state, announced Thursday a plan to revamp the way it negotiates prescription drug prices that it says will lower costs for consumers. Read more from the San Francisco Chronicle, The Sacramento Bee, and Stat.
A Peek at Big Pharma’s Playbook That Leaves Many Americans Unable to Afford Their Drugs
By Elisabeth Rosenthal
Brand-name drug prices in the U.S. — more than three times the price in other developed countries — are related neither to the amount of research and development required to bring them to market nor their therapeutic value, recent research shows. Have drugmakers overplayed their hand?
A New Medicare Proposal Would Cover Training for Family Caregivers
By Judith Graham
The federal government is proposing having Medicare pay professionals to train family caregivers how to perform tasks like bathing and dressing their loved ones, and properly use medical equipment.
Estrategias comerciales de las grandes farmacéuticas dejan a estadounidenses sin poder comprar sus medicamentos
By Elisabeth Rosenthal
Sin barreras, los precios de algunos medicamentos existentes se han disparado, incluso cuando han caído drásticamente en otros países. Los nuevos medicamentos tienen precios enormes, respaldados por el lobby y el marketing.
KFF Health News' 'What the Health?': Abortion Pill’s Legal Limbo Continues
A federal appeals court issued a split decision on whether the abortion pill mifepristone should remain on the market — rejecting a lower court’s decision to effectively cancel the drug’s FDA approval in 2000, while ordering the rollback of more recent rules that made the drug easier to obtain. Nothing changes immediately, however, as the Supreme Court blocked the lower court’s ruling in the spring. It will be up to the high court to determine whether the pill remains available in the U.S. and under which conditions. Sarah Karlin-Smith of the Pink Sheet, Alice Miranda Ollstein of Politico, and Shefali Luthra of The 19th join KFF Health News’ chief Washington correspondent, Julie Rovner, to discuss these issues and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
Daily Edition for Thursday, August 17, 2023
State Reconsidering Who Is Eligible For Medi-Cal: About 15.5 million Californians — including over 150,000 people across the Bay Area — will have their Medi-Cal eligibility reconsidered. As of June, 21% of Medi-Cal recipients in California — or approximately 225,000 people — have lost coverage as a result of the redetermination process, according to the California Department of Health Care Services. Read more from CBS/Bay City News Service.
